Vifor Clinches Deal For Travere's Rare Kidney Disorder Drug

Pays $55m Upfront For Sparsentan

The Swiss group has delivered on its promise to secure more deals in the nephrology space by bagging the rights in Europe, Australia and New Zealand to sparsentan, which is deep into a Phase III program for focal segmental glomerulosclerosis and IgA nephropathy.

Agreement business handshake partnership deal as a solution strategy with a team coming together out of tangled twisted roads on to a bridge to find a common goal.

Having recently pledged to sign at least two deals by the end of 2021, Vifor Pharma Group  has inked the first one and licensed Travere Therapeutics, Inc.'s investigational rare kidney disease drug sparsentan.

The Swiss firm is paying $55m upfront to get hold of the rights in Europe, Australia and New Zealand to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Genitourinary

More from Therapeutic Category